Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Generalized Seizure Clear all
Completed Phase 3 Interventional Results available

Clobazam in Patients With Lennox-Gastaut Syndrome

NCT00518713
View directory record Official record
Conditions
Epilepsy, Epilepsy, Generalized, Seizures
Interventions
Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
2 Years to 60 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
34
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 22, 2026, 2:02 AM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

NCT02408523
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753
View directory record Official record
Conditions
Primary Generalized Epilepsy
Interventions
Cenobamate, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 2:02 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy
Interventions
LP352
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 66 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Active, not recruiting Phase 2 Interventional

RNS System LGS Feasibility Study

NCT05339126
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

NCT01243177
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
16 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 22, 2026, 2:02 AM EDT
Not listed No phase listed Observational

Seizure Detection and Warning System for Epilepsy Patients

NCT01874600
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Sentinel Seizure Detection Device and Warning System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
13 Years to 21 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 22, 2026, 2:02 AM EDT
Withdrawn Phase 2 Interventional

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT00567424
View directory record Official record
Conditions
Epilepsy
Interventions
GW273225
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452
View directory record Official record
Conditions
Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions
Ethosuximide, Lamotrigine, Valproic acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
30 Months to 13 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Not applicable Interventional

EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System

NCT05059002
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
Physiological signal monitoring and seizure detection
Device
Lead sponsor
EpiWatch, Inc.
Industry
Eligibility
5 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study

NCT00041951
View directory record Official record
Conditions
Childhood Absence Epilepsy, Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jul 22, 2026, 2:02 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

NCT06425159
View directory record Official record
Conditions
Generalized Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Not listed Not applicable Interventional

Study to Validate Novel Seizure-Detection Algorithm

NCT04291716
View directory record Official record
Conditions
Seizures, Motor, Seizures, Seizure Disorder, Epilepsy, Epileptic Seizures, Epileptic
Interventions
Motor Seizure Detection Algorithm (mSDA)
Device
Lead sponsor
Overwatch Digital Health
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 22, 2026, 2:02 AM EDT
Recruiting Phase 3 Interventional

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394
View directory record Official record
Conditions
Dravet Syndrome
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Comorbidities in Epilepsy Using Eye Movement Recordings

NCT06310772
View directory record Official record
Conditions
Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
Interventions
Not listed
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

NCT02849626
View directory record Official record
Conditions
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
29
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 22, 2026, 2:02 AM EDT
Withdrawn Not applicable Interventional

Treatment Resistant Epilepsy and N-Acetyl Cysteine

NCT02054949
View directory record Official record
Conditions
Autistic Disorder, Seizures, Irritability
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Clobazam in Subjects With Lennox-Gastaut Syndrome

NCT00162981
View directory record Official record
Conditions
Epilepsy, Epilepsy, Generalized, Seizures
Interventions
Clobazam Low Dose, Clobazam High Dose
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
2 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 22, 2026, 2:02 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 22, 2026, 2:02 AM EDT